OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
EAST RUTHERFORD, N.J., Oct. 12, 2017 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.
The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2,800 liter hydrogenator and 1,500mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.
“We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API business as patents on these begin to expire,” commented Aldo Magnini, Managing Director, Cambrex Milan. “This investment is consistent with the Cambrex strategic plan to increase the company’s small molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.”
This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24M, 4,500 sq. ft. highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: [email protected]
